Archive · 20 Jun 2025
Semaglutide: New Weight Loss Drugs to Launch in India
Semaglutide, known as Ozempic and Wegovy, is a popular drug for diabetes and weight loss.
Novo Nordisk is bringing it to India.
There's a patent, and companies are challenging it to make cheaper versions.
These drugs work like a natural hormone, helping control blood sugar and appetite.
While the tablet form exists, the injectable version is coming.
There are also other similar drugs, like Mounjaro.
However, these drugs can have side effects, and stopping them might lead to weight gain.
Multiple Indian companies aim to produce semaglutide, potentially reducing costs.
Novo Nordisk is set to launch injectable semaglutide (Wegovy/Ozempic) in India for weight loss and diabetes.
Semaglutide is the active ingredient in Ozempic and Wegovy, with a key patent expiring in some markets in early 2026.
The tablet version of semaglutide is already available in India for around ₹10,000 per month.
Eli Lilly launched Mounjaro in India, another injectable drug for weight loss and diabetes.
Indian drugmakers are planning to produce semaglutide, which may lower prices.
- Who
- Novo Nordisk, Dr. Reddy’s Laboratories (DRL), Eli Lilly, and other Indian drugmakers.
- What
- The introduction and competition surrounding semaglutide-based drugs for weight loss and diabetes in India.
- When
- Novo Nordisk is set to launch Wegovy in India; patent expiry in some markets early 2026.
- Where
- India's pharmaceutical market.
- Why
- To address diabetes and obesity with new drug options and compete in the growing market.
Drug Manufacturers
Medical Experts
Market Availability vs Safety
Drug Manufacturers
Focus on bringing new treatments to market and market share.
Medical Experts
Concerns on safety and potential for adverse effects.
- Drug Names
- Semaglutide (Ozempic, Wegovy), Mounjaro (Zepbound)
- Primary Use
- Diabetes & Weight Loss
- Active Ingredient
- Semaglutide, Tirzepatide
- Available Form
- Injectable, Tablet
- Existing Tablet Cost
- ₹10,000/month
- Mounjaro Cost (at launch)
- ₹3,500-₹4,375
- Companies Involved
- Novo Nordisk, Eli Lilly, Cipla, Lupin, Glenmark